

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5754818

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NARESH KUMAR	04/04/2019
RECEIVING PARTY DATA	
Name:	Eli Lilly and Company
Street Address:	Lilly Corporate Center
Internal Address:	Patent Division
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46285
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16500947
CORRESPONDENCE DATA	
Fax Number:	(317)276-3861
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patents@lilly.com
Correspondent Name:	ELI LILLY AND COMPANY
Address Line 1:	P. O. BOX 6288
Address Line 2:	PATENT DIVISION
Address Line 4:	INDIANAPOLIS, INDIANA 46206-6288
ATTORNEY DOCKET NUMBER:	X21853
NAME OF SUBMITTER:	MANDY TAYLOR
SIGNATURE:	/Mandy Taylor/
DATE SIGNED:	10/04/2019
Total Attachments: 2	
source=X21853 WO Assignment-KUMAR#page1.tif	
source=X21853 WO Assignment-KUMAR#page2.tif	

ASSIGNMENT

WHEREAS, I

Naresh KUMAR of Hawthorne, NY
Citizenship: IN

am an inventor of an invention that is the subject of a patent application ("Application") which is entitled CD226 AGONIST ANTIBODIES, for filing:

in the United States Patent and Trademark Office on _____
and accorded Serial Number _____,

in the _____ on _____
and accorded Serial Number _____,

in the Spanish Patent Office as a European Application on _____
and accorded Serial Number _____,

as an international application under the Patent Cooperation Treaty ("PCT"),
with United States Patent and Trademark Office acting as Receiving Office on
19 July 2019 and accorded Serial Number PCT/US2019/042604

as an international application under the Patent Cooperation Treaty ("PCT"),
with The State Intellectual Property Office (SIPO) of China acting as Receiving
Office on _____ and accorded Serial Number _____,

which claims the benefit of priority application Serial Numbers 62/795,744, filed
January 23, 2019 and 62/703,522, filed July 26, 2018.

I hereby give permission to insert above the serial number(s) and filing date(s) for the
application when known.

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal
place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the
entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related
thereto, or other good and valuable consideration, the receipt of which is hereby
acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns
(collectively "Lilly") my entire right, title and interest in, to and under the Application, including
all priority rights for other countries arising therefrom, all inventions therein disclosed, and any
and all present or future patent applications to such inventions that may be filed in any country,
inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions,
reexaminations, reissues, international applications filed under the PCT, United States
provisional patent applications, subsequent United States provisional patent applications
claiming some or all of this invention, certificates of addition, utility models, petty patents, as
well as all other intellectual property related to the Application, inclusive of, but not limited to,
supplementary protection certificates; and any related patent term extensions which may be
granted for Letters Patent with respect to the Application; all of the above to be held and
enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which

such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

04/04/19
Date

Naresh KUMAR
Naresh KUMAR

ACCEPTED AS OF THE DATE ABOVE BY:

[Signature]
Authorized Representative
for ELI LILLY AND COMPANY

Printed Name GRANT E. REED
Title ASSOCIATE GENERAL COUNSEL